PH 50

Drug Profile

PH 50

Alternative Names: N-1177; PH-50

Latest Information Update: 08 Jul 2011

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Elan Corporation; IMCOR Pharmaceutical
  • Class Iodinated contrast media
  • Mechanism of Action Emission-computed tomography enhancers; Radiography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer metastases; Coronary artery disease

Most Recent Events

  • 14 May 2007 Discontinued - Phase-I for Cancer metastases diagnosis in USA (IV)
  • 05 Feb 2004 Photogen Technologies is now called IMCOR Pharmaceutical
  • 02 Apr 2001 Phase-I clinical trials for Cancer metastases diagnosis in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top